BIOPHYTIS.jpg
Biophytis Reports H1 2021 Financial Results and Provides Business Update
September 17, 2021 02:00 ET | BIOPHYTIS SA
SARA-INT: Positive top line results of Phase 2 study demonstrate efficacy of Sarconeos (BIO101) in sarcopenia and support progress into Phase 3COVA: DMC second interim analysis shows efficacy results...
BIOPHYTIS.jpg
Biophytis Announces DMC Second Interim Analysis Efficacy Results in the Promising Zone Allowing Continuation of Phase 2/3 COVA Study With Sarconeos (BIO101) in COVID-19
September 15, 2021 02:00 ET | BIOPHYTIS SA
The independent DMC (Data Monitoring Committee) recommends continuation of Part 2 of the Phase 2-3 Study (“the COVA Study”) without any protocol amendmentThe second Interim Analysis (“IA2”) based on...
BIOPHYTIS.jpg
Biophytis to Attend Key Upcoming Investor Events and Industry Conferences
September 14, 2021 02:00 ET | BIOPHYTIS SA
PARIS and CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of...
BIOPHYTIS.jpg
Biophytis Leadership is Reinforced With New Chief Medical Officer Appointment
September 09, 2021 02:00 ET | BIOPHYTIS SA
Rob van Maanen MD, MBA, FFPM, becomes Chief Medical Officer, member of the Executive Committee PARIS and CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext...
BIOPHYTIS.jpg
Biophytis Receives Favorable Recommendation From Data Monitoring Committee (DMC) Based on Safety Analysis of Sarconeos (BIO101) to Continue Patient Recruitment in the COVA Study in COVID-19
August 16, 2021 02:00 ET | BIOPHYTIS SA
The independent DMC (Data Monitoring Committee) of the COVA study recommends to continue patients recruitment into Part 2 of the phase 2-3 study following randomization of the first 155...
BIOPHYTIS.jpg
Biophytis Announces the Issue of 4,950,000 New Shares in a Capital Increase Reserved for NEGMA and the Performance of the Judgments of March 16, 2021 and July 16, 2021
August 13, 2021 17:00 ET | BIOPHYTIS SA
PARIS and CAMBRIDGE, Mass., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “company”), a clinical-stage biotechnology company...
BIOPHYTIS.jpg
Biophytis Announces Top Line Results of SARA-INT Phase 2 Study With Sarconeos (BIO101) in Sarcopenia
August 02, 2021 02:00 ET | BIOPHYTIS SA
Sarconeos (BIO101) at the highest dose (350 mg bid) showed a clinically meaningful improvement in the 400-meter walk test (400MWT), the primary endpoint of the studySarconeos (BIO101) showed a very...
BIOPHYTIS.jpg
Judgment Rendered on July 16, 2021 in the Proceedings Between Biophytis and Negma Group Ltd by the Execution Judge From the Paris Court of Justice
July 19, 2021 17:00 ET | BIOPHYTIS SA
PARIS and CAMBRIDGE, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company...
BIOPHYTIS.jpg
Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 at ECCMID 2021
July 12, 2021 02:00 ET | BIOPHYTIS SA
PARIS and CAMBRIDGE, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “company”), a clinical-stage biotechnology company...
BIOPHYTIS.jpg
Biophytis Reinforces Leadership Teams with Three Senior Appointments
July 08, 2021 02:00 ET | BIOPHYTIS SA
Claude Allary to be member of Board of Directors Benoit Canolle is appointed Chief Business OfficerJean Mariani, Chairman of Biophytis Scientific Committee to take over the Chief Medical Officer role ...